Foresight Diagnostics to Present Clinical Performance Data on Foresight CLARITY™ MRD at IASLC 2025 World Conference on Lung Cancer

BOULDER, Colo., Sept. 5, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, today announced an oral presentation in partnership with University Health Network's (UHN) Princess Margaret Cancer Centre at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer on September 6-9, 2025, in Barcelona, Spain. The presentation will feature analysis of MRD performance in a cohort of stage I lung cancer patients from the ctDNA-Lung DETECT study using Foresight CLARITY^™, the company's ultrasensitive circulating tumor DNA (ctDNA) assay with a reported detection limit of less than one part per million.¹

Foresight CLARITY^™ demonstrated high ctDNA-MRD detection rates at both pre- and post-operative timepoints. Highlights include:

• Pre-operative MRD detection was 68% and post-operative MRD detection was 38%.
• Clinical sensitivity for relapse detection at post-surgical landmark was 55%, with a median lead time of 10 months prior to clinical recurrence.
• Post-operative MRD detection was significantly associated with worse recurrence-free survival (RFS) at both post-operative landmark (HR = 3.14, p = 0.0425) and at the one-year timepoint (HR = 8.20, p = 0.0001).

"The field has historically recognized the challenges of using ctDNA-MRD assays in early-stage lung cancer, particularly due to the low-shedding nature of these tumors. However, based on the results of our study, ultrasensitive assays can offer actionable insights and may help us achieve personalized treatment strategies, such as adjuvant therapy escalation in high-risk patients," said Dr. Natasha Leighl, Division Head, Medical Oncology and Hematology, UHN's Princess Margaret Cancer Centre, Toronto.

"Detecting MRD in early-stage lung cancer patients before or after surgery may open new clinical applications not possible with current tools," said David Kurtz, Md, PhD, Chief Medical Officer and Head of Research at Foresight Diagnostics. "We look forward to continuing to support innovative studies that advance precision medicine for lung cancer."

Presentation Details:

Ultrasensitive MRD improves detection in resectable stage I NSCLC

• Presenter: Natasha Leighl, BSc, MMSc, MD (Division Head, Medical Oncology and Hematology, UHN's Princess Margaret Cancer Centre, Toronto, Canada)
• Date: Sunday, September 7^th, 2025
• Time: 3:15pm – 4:30pm CEST
• Session: MA03. New Advances in Circulating Biomarkers

To meet with the Foresight Diagnostics team at IASLC 2025, please contact us here or email [email protected].

1 Cabel, et al. SABCS 2024

Foresight CLARITY™ is for research use only and is not intended for use in diagnostic procedures.

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY^™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY^™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky.

About University Health Network (UHN)
UHN is Canada's Hospital. With 10 sites and more than 44,000 TeamUHN members, UHN consists of Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education and West Park Healthcare Centre. As Canada's top research hospital, the scope of biomedical research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. UHN has the largest hospital-based research program in Canada, with major research in neurosciences, cardiology, transplantation, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. UHN is a research hospital affiliated with the University of Toronto. www.uhn.ca

SOURCE Foresight Diagnostics, Inc.